On Monday, Arcutis Biotherapeutics Inc (NASDAQ: ARQT) opened higher 6.21% from the last session, before settling in for the closing price of $10.14. Price fluctuations for ARQT have ranged from $1.76 to $13.17 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 303.42%. Company’s average yearly earnings per share was noted 64.44% at the time writing. With a float of $102.94 million, this company’s outstanding shares have now reached $117.05 million.
Considering the fact that the conglomerate employs 296 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 89.43%, operating margin of -131.16%, and the pretax margin is -140.72%.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Arcutis Biotherapeutics Inc is 12.05%, while institutional ownership is 102.99%. The most recent insider transaction that took place on Nov 22 ’24, was worth 162,515. Before that another transaction happened on Nov 19 ’24, when Company’s See Remarks sold 1,775 for $9.68, making the entire transaction worth $17,190. This insider now owns 181,373 shares in total.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.72 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.8) by 0.08. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.34 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 64.44% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.80% during the next five years compared to -48.07% drop over the previous five years of trading.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Check out the current performance indicators for Arcutis Biotherapeutics Inc (ARQT). In the past quarter, the stock posted a quick ratio of 2.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.28 in the next quarter and is forecasted to reach -0.97 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Compared to the last year’s volume of 3.2 million, its volume of 1.55 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 71.62%. Additionally, its Average True Range was 0.66.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 81.28%, which indicates a significant increase from 73.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 69.32% in the past 14 days, which was higher than the 64.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.57, while its 200-day Moving Average is $9.54. Nevertheless, the first resistance level for the watch stands at $11.18 in the near term. At $11.58, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.07. If the price goes on to break the first support level at $10.29, it is likely to go to the next support level at $9.80. Should the price break the second support level, the third support level stands at $9.40.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
There are currently 117,045K shares outstanding in the company with a market cap of 1.25 billion. Presently, the company’s annual sales total 59,610 K according to its annual income of -262,140 K. Last quarter, the company’s sales amounted to 44,760 K and its income totaled -41,540 K.
